Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Musculoskeletal and connective tissue disorders – page 6

  • 872 clinical trials
  • 359 recruiting
  • 331 conditions
  • 28 countries

Conditions in this area

331 conditions with trials, the busiest first

Rheumatoid arthritis75Osteoarthritis63Systemic lupus erythematosus63Psoriatic arthropathy46Myasthenia gravis44Systemic scleroderma40Sjogren's syndrome31Duchenne muscular dystrophy28Soft tissue sarcoma28Axial spondyloarthritis21Juvenile idiopathic arthritis21Back pain19Ewing's sarcoma19Lupus nephritis18Spinal muscular atrophy17Dermatomyositis16Cutaneous lupus erythematosus14Glycogen storage disease type II14Myotonic dystrophy12Osteochondrodysplasia12Osteosarcoma12Rhabdomyosarcoma11Sarcoma11Osteoporosis10+307

Clinical trials in Musculoskeletal and connective tissue disorders

872 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

872 clinical trials

Short stature+1

Recruiting

Study of Lonapegsomatrin and Somatropin in Children and Adolescents with Short Stature or Growth Failure due to Turner Syndrome, SHOX Deficiency, SGA, or Idiopathic Short Stature

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Lonapegsomatropin
  • Sponsor:Ascendis Pharma Endocrinology Division A/S

Myasthenia gravis

Recruiting

A study to evaluate the safety and effectiveness of empasiprubart and efgartigimod alfa in patients with generalized myasthenia gravis.

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Myasthenia gravis

Recruiting

A study of IM-101 in adults with generalized myasthenia gravis or ocular myasthenia gravis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:IM-101
  • Sponsor:Immunabs Inc.

Immunoglobulin G4 related disease

Recruiting

A study to evaluate the safety and effects of inebilizumab in children and adolescents with immunoglobulin G4-related disease

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Still's disease+1

Recruiting

A study to evaluate the long-term safety of apremilast in children with oral ulcers from Behçet’s disease or juvenile psoriatic arthritis

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years
  • Substances:Apremilast
  • Sponsor:Amgen Inc.

Osteogenesis imperfecta

Recruiting

A safety study of romosozumab in children and adolescents with osteogenesis imperfecta

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Romosozumab
  • Sponsor:Amgen Inc.

Systemic lupus erythematosus

Recruiting

Evaluation of Long-Term Safety and Efficacy of Litifilimab in Adults with Active Systemic Lupus Erythematosus: A Phase 3 Multicenter, Randomized, Dose-Blind Study

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Arthritis infective

Recruiting

A study testing prednisone combined with antibiotics compared to antibiotics alone in adults with septic arthritis to improve joint health

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Assistance Publique Hopitaux De Paris

Lupus nephritis

Recruiting

A Study of Prednisolone, Mycophenolate Mofetil and Voclosporin Compared to Prednisolone and Mycophenolate Mofetil in Patients with Lupus Nephritis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years · Healthy volunteers
  • Substances:Voclosporin
  • Sponsor:Amsterdam UMC Stichting

Glycogen storage disease type II

Recruiting

A Study of S-606001 Added to Enzyme Replacement Therapy for Patients with Late-Onset Pompe Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Sponsor:Shionogi B.V.

Osteochondrodysplasia

Recruiting

A study testing the safety and effectiveness of infigratinib compared to placebo in infants and young children with achondroplasia

Investigational
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Infigratinib
  • Sponsor:Qed Therapeutics Inc.

Myotonic dystrophy

Recruiting

A study testing the safety and effects of ADS-019 in adults aged 18 to 65 years with type 1 myotonic dystrophy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:ADS-019
  • Sponsor:Sarepta Therapeutics Inc.

Substances studied in this area

The therapies tested most often in Musculoskeletal and connective tissue disorders trials.

Sodium Chloride47 clinical trialsParacetamol32 clinical trialsTocilizumab29 clinical trialsMethotrexate26 clinical trialsAdalimumab24 clinical trialsRituximab23 clinical trialsCyclophosphamide20 clinical trialsEtanercept20 clinical trialsBaricitinib17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.